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a b s t r a c t
Artemisinin is one of the most potent anti-malaria drugs and many often-lengthy routes have been devel-
oped for its synthesis. Amorphadiene synthase, a key enzyme in the biosynthetic pathway of artemisinin,
is able to convert an oxygenated farnesyl diphosphate analogue directly to dihydroartemisinic aldehyde,
which can be converted to artemisinin in only four chemical steps, resulting in an efficient synthetic
route to the anti-malaria drug.
 2017 Published by Elsevier Ltd.
1. Introduction
Malaria affects almost 50% of the world’s population and causes
hundreds of thousands of deaths each year.1 Isolated from the
plant Artemisia annua (qinghaosu), the sesquiterpene artemisinin
(1) exhibits excellent anti-malaria activity and kills the parasite
at most of its asexual stages of development in human blood.2
Artemisinin-based combination treatments (ACTs) are widely used
as the first-line treatment for malaria.3 Although several synthetic
routes to artemisinin (1) have been developed,4 the chemical syn-
thesis is lengthy and low yielding due to the highly complex struc-
ture of the sesquiterpene endoperoxide. The worldwide supply of
artemisinin (1) relies predominantly on the extraction of (1) from
the plant Artemisia annua5 and as a consequence the world market
price is highly volatile ranging from US $350 to $1700 per kilo-
gram.6 Most countries affected by malaria epidemics are in the
developing world, and therefore a stable and affordable supply of
artemisinin (1) is highly desirable.
Currently themost efficient synthetic route to produce artemisi-
nin is the combination of a biosynthetic process with several chem-
ical steps (Scheme 1). The biosynthesis of artemisinin is well
understood7 and the key step to this synthesis involves the class I
sesquiterpene cyclase amorphadiene synthase (ADS). This enzyme
catalyses the cyclisation of (E,E)-farnesyl diphosphate (FDP, 2) to
amorpha-4-11-diene (3), a bicyclic intermediate with four stereo-
centres. 3 can be converted to the advanced synthetic intermediate
dihydroartemisinic acid (DHAA, 4) either chemically8a or
enzymatically using engineered yeast (Scheme 1).8b,c The latter
method has been developed into a semi-synthetic production of
artemisinin (1). Engineered yeast containing ADS and five other
enzymes produce artemisinic acid (5), which is subsequently
reduced to DHAA (4) by a transition metal-catalysed
hydrogenation.8a,9 DHAA (4) can then be converted to artemisinin
(1) in three well-established steps.10 The pharmaceutical company
Sanofi developed a commercial route for biosynthetically produced
artemisinin in 2014, but this process has now discontinued due to
strong market forces.11 Alternative routes for the low-cost produc-
tion of artemisinin (1) are therefore urgently required.
Here we report a novel synthetic route to artemisinin (1) start-
ing from the oxygenated farnesyl diphosphate analogue
12-hydroxyfarnesyl diphosphate (6) (Scheme 2). Amorphadiene
synthase (ADS) is able to convert 6 in a single step to dihy-
droartemisinic aldehyde (DHAAl, 7), an advanced intermediate of
artemisinin.12 This route does not proceed via amorphadiene (3)
and therefore avoids several redox steps. Increasing the oxidation
state at the linear precursor stage produces a two-step synthesis
of 4, which significantly shortens the synthesis of artemisinin (1).
2. Enzymatic reaction
ADS catalyses the Mg2+-dependent, highly chemo- and stereos-
elective cyclisation of FDP (2) to amorphadiene (3) (Scheme 3).13
ADS cleaves the CAO bond in 2 and generates diphosphate and a
carbocation, which rearranges through a series of ring closures
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and hydride transfer processes. The last step in the enzymatic
sequence is the deprotonation of amorphyl cation (8) to yield
amorphadiene (3) (Scheme 3).
The enzyme’s remarkable ability to convert a linear precursor to
a structurally and stereochemically complex cyclic product offers a
very efficient synthetic route to terpenes. Sesquiterpene synthases
are not only highly effective and often stereospecific in the reac-
tions they catalyse, many of them also display some degree of sub-
strate promiscuity and some analogues of FDP (2) can be converted
to modified terpenoids.14 As an example, it has been shown that
ADS catalyses the cyclisation of 12-hydroxy FDP (6) to produce
dihydroartemisinic aldehyde (7) (Scheme 4) with a 34% yield.12
The seemingly moderate yield is common for sesquiterpene
cyclases as the reaction is limited by the release of the hydrocarbon
products from the aqueous incubation media.15 Aldehyde 7 is a
well-established intermediate in the biosynthesis of artemisinin
(1).7 In contrast to the three redox steps required to convert (3)
Scheme 1. Synthesis of artemisinin (1) from farnesyl diphosphate (2).
Scheme 2. Schematic synthesis of artemisinin (1) from 12-hydroxyfarnesyl diphosphate (6).
Scheme 3. Biosynthetic pathway to amorpha-4,11-diene (3).
Scheme 4. ADS-catalysed cyclisation of 12-hydroxyfarnesyl diphosphate (7).
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to (7), consisting of an allylic oxidation of amorphadiene to dihy-
droartemisinic alcohol, further oxidation to the corresponding
aldehyde and a final reduction to dihydroartemisinic aldehyde,9c
our approach yields aldehyde 7 in a single step starting from a
linear FDP precursor.
3. Synthesis of 12-hydroxyfarnesyl diphosphate (7)
12-Hydroxyfarnesyl diphosphate (6) was synthesised in three
steps starting from commercially available (E,E)-farnesol (10)
(Scheme 5). Chlorination of 10 gave farnesyl chloride (11) in a
quantitative yield, which was carried forward without purification.
The following step was a selenium dioxide-catalysed oxidation at
C12 of 11.16 The reaction conditions for the allylic oxidation were
optimised, but the yield was still moderate due to the instability
of the product 12-hydroxy farnesyl chloride (12) and the formation
of a by-product resulting from the allylic oxidation at C8. Com-
pound 12 was finally diphosphorylated17 under standard condi-
tions to afford 6.
4. Synthesis of artemisinin
The single step production of 7 provided a great opportunity to
shorten the synthesis of artemisinin. The key intermediate DHAA
(4) is the starting point for many syntheses developed for artemi-
sinin (1).18 The conversion of 4 to 1 can be achieved by reaction
with singlet oxygen followed by air oxidation.10,11 The commercial
route developed by Sanofi used engineered yeast to produce arte-
misinic acid (5),9 which was then hydrogenated with a transition
metal catalyst to yield DHAA (4). Seeberger et al. developed a con-
tinuous flow process to convert DHAA (4) to artemisinin (1) obtain-
ing 4 from the plant Artemisia annua.10
In our approach, DHAA (4) was obtained from the enzyme-
produced aldehyde 7 by a simple oxidation with sodium chlorite4b
in 93% yield (Scheme 6). Acid 4 was then converted to
dihydroartemisinic methyl ester (13) with trimethylsi-
lyldiazomethane in 94% yield.19 The final stage for the synthesis of
artemisinin is a singlet oxygen oxidation of 13 by lithium molyb-
date-catalysed disproportion of hydrogen peroxide.20,9a The crude
product from the singlet oxygen oxidation step was taken into a
hydrocarbon solvent in the presence of trifluoroacetic acid and pure
oxygen.21 After two days, artemisinin (1) was formed as evidenced
by NMR. At this stage, the epimeric mixture can be separated by
standard columnchromatography. An isolated yield cannot be given
due to the small scale of this reaction. Work is on going to evaluate
biological activity of the unnatural epimer.
5. Conclusion
A novel concise synthetic route to artemisinin (1) was devel-
oped. The process benefits from a new chemoenzymatic reaction
between amorphadiene synthase and 12-hydroxyfarnesyl diphos-
phate (6). Due to its relaxed substrate selectivity, ADS accepts
the oxygenated FDP analogue 6 to generate dihydroartemisinic
aldehyde (7), which can be converted to artemisinin (1) in four
steps. Different from any known synthetic route for artemisinin
(1), this approach exploits the promiscuity of terpene synthases.
Oxidation of FDP prior to cyclisation allows the ADS catalysed for-
mation of a much-advanced intermediate on the pathway to arte-
misinin. The whole process only utilised one enzyme combined
with known chemistry. This new route may have potential to be
developed into a low-cost supply of this important antimalarial
drug.
6. Experimental section
6.1. General remarks
All chemicals were purchased from Sigma-Aldrich, Acros Chem-
icals, Fluorochem or Alfa Aesar and used without further purifica-
tion unless otherwise stated. Anhydrous acetonitrile was obtained
from a MBraun SPS800 solvent purification system unless other-
wise stated. Flash column chromatography was performed using
Biotage Flash Purification system. 1H NMR and 13C NMR spectra
were measured on a Bruker Avance 500 NMR spectrometer and
Bruker Avance DPX400 spectrometer. 1H NMR and 13C NMR spec-
tra are reported as chemical shifts in ppm downfield from TMS and
J values are given in Hertz. 31P NMR spectra were recorded on Bru-
ker Avance DPX400 spectrometer or Bruker Avance 500 NMR spec-
trometer and are reported in chemical shifts downfield from 85%
H3PO4. Reverse phase HPLC was performed on a system comprising
of a Dionex P680 pump and a Dionex UVD170U detector unit.
6.2. Preparation of ADS
6.2.1. General methods
LB media was prepared by dissolving tryptone (10 g), yeast
extract (5 g) purchased from Fluka and NaCl (10 g) in 1 L of deio-
nised water. Cell lysis buffer for ADS was prepared by dissolving
trizma-HCl (50 mM), NaCl (500 mM), 2-mercaptoethanol
(20 mM) and glycerol (10% v/v) in deionised water. The final pH
was adjusted to 8.0. Dialysis buffer for ADS was prepared by dis-
solving HEPES (25 mM), NaCl (100 mM) and dithiothreitol
(1 mM) in deionised water. The final pH was adjusted to 7.5.Scheme 5. Synthesis of 12-hydroxyfarnesyl diphosphate (6).
Scheme 6. Synthesis of artemisinin (1) from 12-hydroxyfarnesyl diphosphate (6).
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6.2.2. Transformation of E. coli BL21 with cDNA for wild-type ADS
Cloning of the ADS gene into pET21d plasmid. The gene coding
for amorphadiene synthase (ADS) from Artemisia annua was
obtained from gene bank (JF951730). It was supplied in a pTrc99a
vector between the NcoI and BamHI restriction sites (pTrc-ADS).
pET21d and pTrc-ADS were digested with the endonucleases NcoI
and BamHI (0.1 lL of each enzyme, 1 lL of buffer, 10 lL of plasmid,
1 h, 37 C) and the fragments ligated using T4 DNA ligase (1:2 M
ratio of pET: ADS, 0.1 lL enzyme, 2 lL of buffer, H2O to make total
volume to 20 lL) to give a new plasmid pET21d-ADS. Supercompe-
tent E. coli XL1-blue cells were transformed with 5 mL of ligated
DNA and stored on ice (30 min) before being heat shocked in a
water bath at 40 C for 40 s and placed on ice for 2 min. LB medium
(1 mL) was added and the solution shaken for 60 min (37 C,
150 rpm). The cells were harvested by centrifugation (3400g,
1 min) and spread on an agar plate containing ampicillin
(100 lg/mL) after resuspending in a minimum amount of buffer.
Plates were incubated overnight at 37 C and then stored at 4 C.
A single colony from the agar plate was used to inoculate 15 mL
of LB medium containing ampicillin (100 lg/mL). The culture
was incubated overnight (37 C) and the following day centrifuged
(3220g, 8 min). The pellet was purified using a QIAprep Spin Mini-
prep Kit (QIAprep Miniprep Handbook-2005). The resulting 50 lL
DNA solution was stored at 20 C. The sequence was confirmed
by DNA sequence analysis (Eurofin).
E. coli BL21 competent cells (stored at 80 C) were slowly
defrosted in ice. Vector containing a cDNA for ADS and resistance
for ampicillin (1 lL) was added to the cells. After leaving on ice
for 20 min, the mixture was thermally shocked in a water bath at
40 C for 35 s and returned to ice for 2 min. LB media (1 mL, ster-
ilised) was added to the transformed cells under flame and the
solution was shaken (150 rpm) at 37 C for 1 h. The cells were sep-
arated from the media by centrifuging the mixture (6000 rpm) for
1 min. The cells were re-suspended in the minimum amount of LB
media and the mixture was spread in an ampicillin-agar plate
under flame. The plate was incubated at 37 C for 12 h.
6.2.3. Overexpression of ADS
The overnight culture was prepared the same way as AS.15b The
resulting mixture was incubated at 37 C and the growth of
bacteria was monitored by checking the OD of media at 600 nm
until it reached 0.5. The culture was induced by isopropyl-1-thio-
b-D-galactopyranoside (60 mg). The induced culture was
incubated at 20 C for 6 h. The solutions were centrifuged at
5000 rpm for 20 min, the supernatant was discarded and the
pellets were stored at 20 C.
6.2.4. Purification of ADS
All the buffers for ADS purificationwere cooled on ice before use.
The pellets were defrosted on ice and re-suspended in cell lysis buf-
fer (40 mL). After adding lysozyme (20 mg), themixture was stirred
at 4 C for 30 min. The solution was sonicated in an ice bath (3 min
with 5 s on/10 s off cycles) then centrifuged at 5000 rpm for 10 min.
The supernatantwas loadedonto aNi2+NTAcolumnandelutedwith
a gradient of imidazole in cell lysis buffer (5 mM to 300 mM). The
protein eluted at 100 mM imidazole. The presence of protein was
confirmed by SDS-PAGE electrophoresis. All the fractions with pro-
tein were combined and dialyzed in dialysis buffer at 4 C for 24 h.
The resulting protein solution was concentrated to 10 mL final vol-
ume. The concentration of ADSwasdeterminedbyBradfordAssay.22
6.3. Synthesis of 12-OH FDP (7)
6.3.1. Farnesyl chloride (11)
Farnesol (10) (2.0 mL, 8 mmol) was dissolved in anhydrous DMF
(80 mL) and cooled to 0 C. Collidine (6.3 mL, 48 mmol) and MsCl
(1.3 mL, 16 mmol) were added to the mixture. After stirring at
0 C for 15 min, anhydrous LiCl (1.35 g, 32 mmol) was added. The
reaction was stirred at 0 C for 3 h. H2O (80 mL) was added and
the mixture was extracted with hexane (50 mL  3). The combined
organic phases were washed with CuSO4 (sat.), NaHCO3 (sat.) and
brine. The resulting solution was dried over anhydrous Na2SO4
and concentrated under reduced pressure. Compound 11 was
obtained as a yellow oil and used in the next step without purifica-
tion. 1H NMR (300 MHz, CDCl3): d (ppm) 5.46 (1H, t, J = 8.0), 5.12–
5.08 (2H, m), 4.12 (2H, d, J = 8.0), 2.23–1.98 (8H, m), 1.73 (3H, s),
1.66 (3H, s), 1.61 (6H, s).
6.3.2. 12-Hydroxyfarnesyl chloride (12)
SeO2 (226 mg, 2.4 mmol), salicylic acid (331 mg, 2.4 mmol) and
tBuOOH (70%, 5.5 mL, 40 mmol) were dissolved in CH2Cl2 (40 mL)
and stirred for 30 min at room temperature. The reaction mixture
was then cooled to 0 C and 11 (1.92 g, 8 mmol) in CH2Cl2 (20 mL)
was added and stirred at 0 C for 17 h. The reaction was quenched
with Na2SO3 (sat.) at 0 C. The mixture was extracted with Et2O
(50 mL  3). The combined organic phases were dried over anhy-
drous Na2SO4 and concentrated under reduced pressure. The crude
oil was purified by flash chromatography on silica gel (CH2Cl2 with
1% NEt3), the eluent used for the column chromatography was
cooled on ice before use and fractions were kept on ice. Compound
12 was obtained as a yellow oil (1.02 g, 49% over two steps). 1H
NMR (300 MHz, CDCl3): d (ppm) 5.46–5.40 (1H, m), 5.41–5.36
(1H, m) 5.10 (1H, m), 4.10 (2H, d, J = 8.0), 3.99 (2H, s), 2.16–1.99
(8H, m), 1.73 (3H, s), 1.66 (3H, s), 1.60 (3H, s); 13C NMR (75 MHz,
CDCl3): d (ppm) 142.7, 135.3, 134.7, 126.0, 123.7, 120.3, 69.0,
41.2, 39.4, 39.3, 26.2, 26.1, 16.1, 16.0, 13.7. HRMS (ES+): calcd for
C15H25OCl[Na]
+: 279.1483, found: 279.1492.
6.3.3. 12-Hydroxyfarnesyl diphosphate (6)
12 (102 mg, 0.4 mmol) and (Bu4N)3HP2O7 (720 mg, 0.8 mmol)
were dissolved in anhydrous MeCN (10 mL). The reaction was stir-
red at room temperature for 17 h. After removing solvent under
reduced pressure, the crude oil was loaded onto an ion-exchange
resin DOWEX 40-W, which was received from Aldrich in H+ form.
The resin was converted into NH4
+ form by washing with concen-
trated NH4OH, followed by deionised water until the pH dropped
to 7 and finally equilibrated with ion-exchange buffer (25 mM
NH4HCO3 containing 2% i-PrOH). The fractions were collected
and lyophilized for 18–24 h. the resulting off-yellow solid was
purified by reverse phase column chromatography (Biotage KP-
C18-HS 12 g column, CV = 15 mL, H2O/MeCN, 0% to 5% MeCN over
10 CV, 10% to 90% MeCN over 5 CV, 90% MeCN for 5 CV, UV collec-
tion 210 nm & 220 nm). The fractions were collected and lyophi-
lized for 18–24 h to give compound 6 as a light white powder
(94 mg, 52% yield). M.p. 132–136 C. 1H NMR (500 MHz, D2O): d
(ppm) 5.41–5.33 (2H, m), 5.15 (1H, t, J = 6.5), 4.40 (2H, t, J = 6.5),
3.88 (2H, s), 2.16–1.96 (8H, m), 1.65 (3H, s), 1.57 (3H, s) and 1.56
(3H, s); 31P NMR (121 MHz, D2O): d (ppm) 7.93, 7.53. HRMS
(ES): calculated for C15H25O8P2[H][Na]
: 419.1001, found:
419.0983.
6.4. Synthesis of artemisinin (1)
6.4.1. Dihydroartemisinic aldehyde (7)
Purified ADS (8.8 mL of 90 mM, 2 mM) and 6 (72 mg, 0.4 mM)
were added to incubation buffer (400 mL, pH = 9.4, Glycine/NaOH)
containing MgCl2 (190 mg, 5 mM). The mixture was overlaid with
pentane (600 mL). The resulting two phased solution was slowly
stirred at 4 C for 2 days. The pentane phase was separated, dried
over anhydrous Na2SO4 and concentrated under reduced pressure.
The crude was purified by flash chromatography (Biotage SNAP
Ultra 10 g, CV = 15 mL, Pet Ether/Et2O, 0% to 10% Et2O over 10 CV,
4 X. Tang et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx
Please cite this article in press as: Tang X., et al. Bioorg. Med. Chem. (2017), http://dx.doi.org/10.1016/j.bmc.2017.03.068
10% to 90% Et2O over 5 CV, 90% Et2O for 5 CV, UV collection 210 nm
& 220 nm). The fractions were collected and concentrated under
reduced pressure. Pure compound 7 were obtained as colourless
oil (12 mg, 34% yield). Compound 7 was isolated as a mixture of
epimers at C11. Ratio of the two epimers were 5:1 with (11S)-7
as the major product. (11S-7): 1H NMR (500 MHz, CDCl3): d
(ppm) 9.62 (1H, d, J = 3.5), 5.26 (1H, bs), 2.48 (1H, m), 2.39 (1H,
m), 1.91–1.25 (11H, m), 1.63 (3H, s), 1.08 (3H, d, J = 7.0), 0.87
(3H, d, J = 6.5). (11R-7): 1H NMR (500 MHz, CDCl3): d (ppm) 9.57
(1H, d, J = 3.5), 5.12 (1H, bs), 2.48 (2H, m), 1.91–1.25 (11H, m),
1.63 (3H, s), 1.08 (3H, d, J = 7.0), 1.06 (3H, d, J = 7.0), 0.87 (3H, d,
J = 6.5).
6.4.2. Dihydroartemisinic acid (4)
Dihydroartemisinic aldehyde (9 mg, 0.04 mmol) was dissolved
in a mixture of t-BuOH (0.4 mL) and 2-methyl-2-butene
(0.05 mL) and cooled down to 0 C. A solution of NaClO2 (22 mg,
0.24 mmol) and NaH2PO4 (48 mg, 0.40 mmol) in deionised water
(0.25 mL) was added and the mixture was stirred at 0 C for
45 min. The reaction mixture was diluted with diethyl ether and
extracted with additional diethyl ether (3  5 mL). The combined
organic phases were washed with brine, dried over anhydrous Na2-
SO4 and concentrated under reduced pressure. The crude mixture
was purified by flash chromatography on silica (diethyl ether/pet-
roleum ether: 1:4 to 1:1) to give dihydroartemisinic acid 4 as
colourless oil (9 mg, 93% yield). (11S-4): 1H NMR (300 MHz,
CDCl3): d (ppm) 5.29 (1H, bs), 2.58–2.50 (1H, m), 2.41 (1H, bs),
1.91–1.78 (3H, m), 1.75–1.54 (3H, m), 1.42 (1H, bs), 1.25–1.17
(2H, m), 1.00–0.92 (2H, m), 1.63 (3H, s), 1.23 (3H, d, J = 8.0), 0.87
(3H, d, J = 6.5); 13C NMR (125 MHz, CDCl3): d (ppm) 182.2, 135.5,
120.6, 45.0, 41.8, 39.4, 35.6, 29.9, 27.8, 26.7, 25.7, 24.9, 24.1,
19.9, 16.4; (11R-4): 1H NMR (500 MHz, CDCl3): d (ppm) 5.12 (1H,
bs), 2.58–2.50 (2H, m), 1.91–1.78 (3H, m), 1.75–1.54 (3H, m),
1.42 (1H, bs), 1.25–1.17 (2H, m), 1.00–0.92 (2H, m), 1.63 (3H, s),
1.21 (3H, d, J = 7.0), 0.87 (3H, d, J = 6.5); 13C NMR (125 MHz, CDCl3):
d (ppm) 183.7, 136.2, 119.5, 43.8, 41.9, 41.6, 36.6, 35.4, 27.9, 27.6,
26.8, 25.9, 24.0, 19.9, 15.3.
6.4.3. Dihydroartemisinic methyl ester (13)
Acid 4 (6 mg, 0.025 mmol) was dissolved in a toluene (0.30 mL)
and methanol (0.20 mL) mixture. TMSCHN2 (0.025 mL, 2.0 M in
Et2O) was added and the mixture was left to stir at room temper-
ature for 30 min. The mixture was diluted with diethyl ether,
quenched with AcOH (10%) and extracted with additional Et2O
(3  5 mL). The combined organic phases were washed with brine,
dried over anhydrous Na2SO4 and concentrated under reduced
pressure. The crude was purified by flash chromatography on silica
(diethyl ether/petroleum ether: 1:9 to 1:4) to give compound 13 as
colourless oil (6 mg, 94% yield). (11S-13): 1H NMR (500 MHz,
CDCl3): d (ppm) 5.27 (1H, bs), 3.73 (3H, s), 2.54–2.49 (1H, m),
2.24 (1H, br), 1.89–1.74 (3H, m), 1.62 (3H, s), 1.66–1.55 (3H, m),
1.51–1.43 (3H, m), 1.16 (3H, br), 0.95–0.93 (2H, m), 0.86 (3H, br);
13C NMR (125 MHz, CDCl3): d (ppm) 177.4, 135.0, 120.4, 51.4,
45.1, 41.6, 39.2, 35.4, 30.3, 27.5, 26.5, 25.5, 24.8, 23.8, 19.7, 16.2;
(11R-13): 1H NMR (500 MHz, CDCl3): d 5.12 (1H, bs), 3.73 (3H, s),
2.54–2.49 (2H, m), 1.89–1.74 (3H, m), 1.62 (3H, s), 1.66–1.55
(3H, m), 1.51–1.43 (3H, m), 1.16 (3H, br), 0.95–0.93 (2H, m), 0.86
(3H, br); 13C NMR (125 MHz, CDCl3): d (ppm) 178.2, 125.5, 119.4,
51.4, 43.9, 42.1, 41.7, 36.4, 35.2, 27.6, 27.4, 26.6, 25.7, 23.8, 19.7,
15.1.
6.4.4. Artemisinin (1)
13 (25 mg, 0.1 mmol) and Li2MoO4 (10 mg, 0.06 mmol) were
suspended in MeOH (1 mL). H2O2 (50%, 200 mL) was added drop-
wise and it was observed that the solution turned dark brown.
The mixture was stirred at room temperature for 17 h. The mixture
was diluted with CH2Cl2 (2 mL) and H2O (2 mL), the organic layer
was separated and the aqueous phase was extracted with CH2Cl2
(3  2 mL). Combined organic extracts were passed through a
phase separator and concentrated under reduced pressure. The
resulting colourless oil was dissolved in petroleum ether (1 mL),
followed by the addition of TFA (5 mL) and H2O (10 mL). The solu-
tion was purged with O2 and stirred at room temperature with
an O2 balloon for two days. H2O (2 mL) and Et2O (2 mL) were added
and the aqueous layer was extracted with Et2O (3  2 mL). The
combined organic phases was dried over anhydrous Na2SO4 and
concentrated under reduced pressure. The crude product was puri-
fied by flash chromatography on silica (ethyl acetate/hexane: 2:8
to 3:7) to give artemisinin (1) (<1 mg). (11S-1): 1H NMR
(500 MHz, CDCl3): d (ppm) 5.93 (1H, s), 3.70–3.67 (1H, m), 2.43–
2.37 (1H, m), 2.29–2.25 (2H, m), 2.17–2.15 (2H, m), 2.08–2.05
(1H, m), 1.97–1.94 (1H, m), 1.82–1.79 (1H, m), 1.73–1.70 (1H,
m), 1.64–1.63 (1H, m), 1.47 (3H, d, J = 8.1 Hz), 1.46 (3H, s) 1.11–
1.19 (1H, m), 1.00 (3H, d, J = 5.4 Hz). 13C NMR (125 MHz, CDCl3):
d (ppm) 172.5, 105.3, 94.0, 77.2, 50.5, 45.5, 39.7, 37.6, 35.9, 34.0,
31.1, 25.5, 24.7, 20.5, 19.9. (11R-1): 1H NMR (500 MHz, CDCl3): d
(ppm) 5.86 (1H, s), 3.38–3.41 (1H, m), 2.44–2.40 (1H, m), 2.07–
1.99 (2H, m), 1.89–1.88 (1H, m), 1.78–1.73 (2H, m), 1.52–1.35
(4H, m), 1.45 (3H, s), 1.21 (3H, d, J = 7.7 Hz), 1.02–1.13 (1H, m),
1.00 (3H, d, J = 5.4 Hz). HRMS calcd for C15H23O5 (M+H
+)
283.1545, found 283.1559.
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